Tecentriq SC (Atezolizumab)
atezolizumab 1.875 g/15 mL injection, 15 mL vial · INJECTION · PBS code 14278L
STREAMLINEDWhat it costs
AU$6747.37 PBS-determined price per 1 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2024-08-01.
- • Repeats: 3.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma
Initial treatment
Patient must be undergoing combination treatment with bevacizumab and atezolizumab until disease progression, unless not tolerated; AND
Patient must have a WHO performance status of 0 or 1; AND
Patient must not be suitable for transarterial chemoembolisation; AND
Patient must have Child Pugh class A; AND
The condition must be untreated with systemic therapy; or
Patient must have developed intolerance to a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) of a severity necessitating permanent treatment withdrawal.
Sponsor: Roche Products Pty Ltd ABN 70 000 132 865
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.